🎉 M&A multiples are live!
Check it out!

Accelerate Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Accelerate Diagnostics and other public comps.

See Accelerate Diagnostics Valuation Multiples

Accelerate Diagnostics Overview

About Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.


Founded

1982

HQ

United States of America
Employees

134

Financials

LTM Revenue $12.0M

LTM EBITDA n/a

EV

$67.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Accelerate Diagnostics Financials

Accelerate Diagnostics has a last 12-month revenue of $12.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Accelerate Diagnostics achieved revenue of $12.1M and an EBITDA of -$49.8M.

Accelerate Diagnostics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Accelerate Diagnostics valuation multiples based on analyst estimates

Accelerate Diagnostics P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $12.8M $12.1M $11.9M $12.0M XXX
Gross Profit -$0.4M $3.3M $2.5M XXX XXX
Gross Margin -3% 27% 21% XXX XXX
EBITDA -$55.8M -$49.8M n/a n/a XXX
EBITDA Margin -438% -413% NaN% 0% XXX
Net Profit -$77.7M -$62.5M -$61.6M XXX XXX
Net Margin -609% -518% -518% XXX XXX
Net Debt $68.2M $38.4M $24.7M XXX XXX

Financial data powered by Morningstar, Inc.

Accelerate Diagnostics Stock Performance

As of February 14, 2025, Accelerate Diagnostics's stock price is $1.

Accelerate Diagnostics has current market cap of $29.6M, and EV of $67.6M.

See Accelerate Diagnostics trading valuation data

Accelerate Diagnostics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$67.6M $29.6M XXX XXX XXX XXX $-2.26

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Accelerate Diagnostics Valuation Multiples

As of February 14, 2025, Accelerate Diagnostics has market cap of $29.6M and EV of $67.6M.

Accelerate Diagnostics's trades at 5.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Accelerate Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Accelerate Diagnostics and 10K+ public comps

Accelerate Diagnostics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $67.6M XXX XXX XXX
EV/Revenue 5.7x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Accelerate Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Accelerate Diagnostics Valuation Multiples

Accelerate Diagnostics's NTM/LTM revenue growth is 3%

Accelerate Diagnostics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Accelerate Diagnostics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Accelerate Diagnostics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Accelerate Diagnostics and other 10K+ public comps

Accelerate Diagnostics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -1% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 210% XXX XXX XXX XXX
Opex to Revenue 469% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Accelerate Diagnostics Public Comps

See valuation multiples for Accelerate Diagnostics public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Philips XXX XXX XXX XXX XXX XXX
Perspective Therapeutics XXX XXX XXX XXX XXX XXX
Electromed XXX XXX XXX XXX XXX XXX
InfuSystem XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Accelerate Diagnostics M&A and Investment Activity

Accelerate Diagnostics acquired  XXX companies to date.

Last acquisition by Accelerate Diagnostics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Accelerate Diagnostics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Accelerate Diagnostics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Accelerate Diagnostics

When was Accelerate Diagnostics founded? Accelerate Diagnostics was founded in 1982.
Where is Accelerate Diagnostics headquartered? Accelerate Diagnostics is headquartered in United States of America.
How many employees does Accelerate Diagnostics have? As of today, Accelerate Diagnostics has 134 employees.
Who is the CEO of Accelerate Diagnostics? Accelerate Diagnostics's CEO is Mr. John Phillips.
Is Accelerate Diagnostics publicy listed? Yes, Accelerate Diagnostics is a public company listed on NAS.
What is the stock symbol of Accelerate Diagnostics? Accelerate Diagnostics trades under AXDX ticker.
When did Accelerate Diagnostics go public? Accelerate Diagnostics went public in 1996.
Who are competitors of Accelerate Diagnostics? Similar companies to Accelerate Diagnostics include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem.
What is the current market cap of Accelerate Diagnostics? Accelerate Diagnostics's current market cap is $29.6M
What is the current revenue of Accelerate Diagnostics? Accelerate Diagnostics's last 12-month revenue is $12.0M.
What is the current EV/Revenue multiple of Accelerate Diagnostics? Current revenue multiple of Accelerate Diagnostics is 5.7x.
What is the current revenue growth of Accelerate Diagnostics? Accelerate Diagnostics revenue growth between 2023 and 2024 was -1%.
Is Accelerate Diagnostics profitable? Yes, Accelerate Diagnostics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.